#BEGIN_DRUGCARD DB02836

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H14N5O13P3

# Chemical_IUPAC_Name:
[({[(3aS,4R,6S,6aS)-6-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-2-hydroxy-2-oxo-tetrahydro-2H-1,3,5,2$l^{5}-furo[3,4-d][1,3,2$l^{5}]dioxaphosphol-4-yl]methoxy}(hydroxy)phosphoryl)oxy]phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Guanosine 5'-Diphosphate 2':3'-Cyclic Monophosphate

# HET_ID:
GPX

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H14N5O13P3/c11-10-13-7-4(8(16)14-10)12-2-15(7)9-6-5(26-31(22,23)27-6)3(25-9)1-24-30(20,21)28-29(17,18)19/h2-3,5-6,9H,1H2,(H,20,21)(H,22,23)(H2,17,18,19)(H3,11,13,14,16)/t3-,5+,6+,9+/m1/s1

# InChI_Key:
InChIKey=NGYWTCOGOZELRS-KHLHZJAASA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2836

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
505.1651

# Molecular_Weight_Mono:
504.980095095

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1VJ7

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.68

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
6.76e+00 g/l

# Primary_Accession_No:
DB02836

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936505

# PubChem_Substance_ID:
46508518

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01643

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC2=C(N=CN2[C@H]2O[C@H](CO[P@](O)(=O)OP(O)(O)=O)[C@@H]3O[P@](O)(=O)O[C@H]23)C(=O)N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:32 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J04199

# Drug_Target_1_GenBank_ID_Protein:
147406

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
purA

# Drug_Target_1_Gene_Sequence:
>1299 bp
ATGGGTAACAACGTCGTCGTACTGGGCACCCAATGGGGTGACGAAGGTAAAGGTAAGATC
GTCGATCTTCTGACTGAACGGGCTAAATATGTTGTACGCTACCAGGGCGGTCACAACGCA
GGCCATACTCTCGTAATCAACGGTGAAAAAACCGTTCTCCATCTTATTCCATCAGGTATT
CTCCGCGAGAATGTAACCAGCATCATCGGTAACGGTGTTGTGCTGTCTCCGGCCGCGCTG
ATGAAAGAGATGAAAGAACTGGAAGACCGTGGCATCCCCGTTCGTGAGCGTCTGCTGCTG
TCTGAAGCATGTCCGCTGATCCTTGATTATCACGTTGCGCTGGATAACGCGCGTGAGAAA
GCGCGTGGCGCGAAAGCGATCGGCACCACCGGTCGTGGTATCGGGCCTGCTTATGAAGAT
AAAGTAGCACGTCGCGGTCTGCGTGTTGGCGACCTTTTCGACAAAGAAACCTTCGCTGAA
AAACTGAAAGAAGTGATGGAATATCACAACTTCCAGTTGGTTAACTACTACAAAGCTGAA
GCGGTTGATTACCAGAAAGTTCTGGATGATACGATGGCTGTTGCCGACATCCTGACTTCT
ATGGTGGTTGACGTTTCTGACCTGCTCGACCAGGCGCGTCAGCGTGGCGATTTCGTCATG
TTTGAAGGTGCGCAGGGTACGCTGCTGGATATCGACCACGGTACTTATCCGTACGTAACT
TCTTCCAACACCACTGCTGGTGGCGTGGCGACCGGTTCCGGCCTGGGCCCGCGTTATGTT
GATTACGTTCTGGGTATCCTCAAAGCTTACTCCACTCGTGTAGGTGCAGGTCCGTTCCCG
ACCGAACTGTTTGATGAAACTGGCGAGTTCCTCTGCAAGCAGGGTAACGAATTCGGCGCA
ACTACGGGGCGTCGTCGTCGTACCGGCTGGCTGGACACCGTTGCCGTTCGTCGTGCGGTA
CAGCTGAACTCCCTGTCTGGCTTCTGCCTGACTAAACTGGACGTTCTGGATGGCCTGAAA
GAGGTTAAACTCTGCGTGGCTTACCGTATGCCGGATGGTCGCGAAGTGACTACCACTCCG
CTGGCAGCTGACGACTGGAAAGGTGTAGAGCCGATTTACGAAACCATGCCGGGCTGGTCT
GAATCCACCTTCGGCGTGAAAGATCGTAGCGGCCTGCCGCAGGCGGCGCTGAACTATATC
AAGCGTATTGAAGAGCTGACTGGTGTGCCGATCGATATCATCTCTACCGATCCGGATCGT
ACTGAAACCATGATTCTGCGCGACCCGTTCGACGCGTAA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
10346917	Choe JY, Poland BW, Fromm HJ, Honzatko RB: Mechanistic implications from crystalline complexes of wild-type and mutant adenylosuccinate synthetases from Escherichia coli. Biochemistry. 1999 May 25;38(21):6953-61.
10364182	Hou Z, Cashel M, Fromm HJ, Honzatko RB: Effectors of the stringent response target the active site of Escherichia coli adenylosuccinate synthetase. J Biol Chem. 1999 Jun 18;274(25):17505-10.
1733940	Liu F, Dong Q, Fromm HJ: Site-directed mutagenesis of the phosphate-binding consensus sequence in Escherichia coli adenylosuccinate synthetase. J Biol Chem. 1992 Feb 5;267(4):2388-92.
2061308	Dong Q, Liu F, Myers AM, Fromm HJ: Evidence for an arginine residue at the substrate binding site of Escherichia coli adenylosuccinate synthetase as studied by chemical modification and site-directed mutagenesis. J Biol Chem. 1991 Jul 5;266(19):12228-33.
2108156	Dong Q, Fromm HJ: Chemical modification of adenylosuccinate synthetase from Escherichia coli by pyridoxal 5'-phosphate. Identification of an active site lysyl residue. J Biol Chem. 1990 Apr 15;265(11):6235-40.
3058695	Wolfe SA, Smith JM: Nucleotide sequence and analysis of the purA gene encoding adenylosuccinate synthetase of Escherichia coli K12. J Biol Chem. 1988 Dec 15;263(35):19147-53.
7490761	Silva MM, Poland BW, Hoffman CR, Fromm HJ, Honzatko RB: Refined crystal structures of unligated adenylosuccinate synthetase from Escherichia coli. J Mol Biol. 1995 Dec 1;254(3):431-46.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
8961938	Poland BW, Lee SF, Subramanian MV, Siehl DL, Anderson RJ, Fromm HJ, Honzatko RB: Refined crystal structure of adenylosuccinate synthetase from Escherichia coli complexed with hydantocidin 5'-phosphate, GDP, HPO4(2-), Mg2+, and hadacidin. Biochemistry. 1996 Dec 10;35(49):15753-9.
9000627	Poland BW, Fromm HJ, Honzatko RB: Crystal structures of adenylosuccinate synthetase from Escherichia coli complexed with GDP, IMP hadacidin, NO3-, and Mg2+. J Mol Biol. 1996 Dec 20;264(5):1013-27.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2632

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
47346

# Drug_Target_1_Name:
Adenylosuccinate synthetase

# Drug_Target_1_Number_of_Residues:
432

# Drug_Target_1_PDB_ID:
1KKF

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00709	Adenylsucc_synt

# Drug_Target_1_Protein_Sequence:
>Adenylosuccinate synthetase
MGNNVVVLGTQWGDEGKGKIVDLLTERAKYVVRYQGGHNAGHTLVINGEKTVLHLIPSGI
LRENVTSIIGNGVVLSPAALMKEMKELEDRGIPVRERLLLSEACPLILDYHVALDNAREK
ARGAKAIGTTGRGIGPAYEDKVARRGLRVGDLFDKETFAEKLKEVMEYHNFQLVNYYKAE
AVDYQKVLDDTMAVADILTSMVVDVSDLLDQARQRGDFVMFEGAQGTLLDIDHGTYPYVT
SSNTTAGGVATGSGLGPRYVDYVLGILKAYSTRVGAGPFPTELFDETGEFLCKQGNEFGA
TTGRRRRTGWLDTVAVRRAVQLNSLSGFCLTKLDVLDGLKEVKLCVAYRMPDGREVTTTP
LAADDWKGVEPIYETMPGWSESTFGVKDRSGLPQAALNYIKRIEELTGVPIDIISTGPDR
TETMILRDPFDA

# Drug_Target_1_Reaction:
GTP + IMP + L-aspartate = GDP + phosphate + N6-(1,2-dicarboxyethyl)-AMP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Plays an important role in the de novo pathway of purine nucleotide biosynthesis

# Drug_Target_1_SwissProt_ID:
P0A7D4

# Drug_Target_1_SwissProt_Name:
PURA_ECOLI

# Drug_Target_1_Synonyms:
AMPSase
AdSS
EC 6.3.4.4
IMP--aspartate ligase

# Drug_Target_1_Theoretical_pI:
5.13

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X72832

# Drug_Target_2_GenBank_ID_Protein:
407881

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
relA

# Drug_Target_2_Gene_Sequence:
>2220 bp
TTAGCCATTGGTCCGCTTCACGCTATAAACATCTGGAACTGCCTTAATTTTTTCGACAAC
AGTTGTCAGATGCGTCAGATTTGGAATGCCAAAGCTCACGTGAATATTCGCAAACTTCAT
GTCCTTGGTTGGCTGGGCATTAACGGTGGAAATACTCTTGGTAGAATTAGACAAAATCTG
GAGGACGTCATTGAGAAGGCCTCTACGATTGAGCCCATAAATATCAATTTCAGCTTGGTA
ATCTTTGCTGGAGTTATCCAAATCCCATTCCACCTCGATGAGACGCTCTTGGTAGCCATC
TTGACTCTTGATGTTATTACAATCCGCACGGTGGATGGCAATGCCTCGACCCTTGGTAAT
ATAGCCTTCAATGGGATCCCCAGGTACAGGATTACAACATTTAGCAATCCGCATCAAGAG
TCCTGAAGCCCCTTGGATAATAACCCCATTTTCACTGCGAACCTTGAGAACATCCTTGTT
TTCGTGCTTGATTTCGCCACCGTTAACCAATTCTTCTGCTTCTGCCTTAGCCTTGGCTCT
TTCCTCTTCACGGCGTTCTTTTTCAGTTAATTTATTAAAGACACTAACAGGACTAATGTC
GCCAAAACCGACCGCTGCGTAGAGAGATTCTTCGCTCTTCACACTGACTTTTGGAAGAAT
AGCTTCTATGCGTTTTTTATCAAGGTATTTATTGGCAACATAGCCCTGCTCTTGGAAATA
AGAAACCAGCATGTCACGGCCTTTATTCACTGACAACTCTTTGTCTTGGTTTTTAAAGAA
CTGACGAATCTTGTTGCGAGCTTTATTGGTTTTTACCAACTTAATCCAGTCACGGCTTGG
CCCAAAAGAGTTAGGGTTGGTGACGATTTCCACCACATCTCCTGTTTTTAATTTGGCTGT
TAGGGGAACCATACGGCCATTAACCTTGGCCCCTATCGCTTTTTCACCCACTTGCGTGTG
GATGGCATAGGCAAAGTCAATTGGTCCCGAGTCCTTTGGCAATTCCTGCACAGCACCTGT
CGGTGTAAAGACGTAAATACGTTCTGAGAAAATGTCTTCTTTGACCGAGTCCACAAAGTC
CACTGCATCGCCATTTGACGCATCTTGTAACTCCACAAGCTCTTTGATCCAGTTCATGCC
AACCTTTTGTTCGGCCTGATTAACCTTGCCGCGGACGCCTTTTTTATAAGCCCAGTGAGC
AGCTACCCCGTACTCAGCCACTTGGTGCATTTCCTTGGTGCGGATTTGAATCTCAATCGG
ACCTTTAGGGCCATACACGGTGGTATGAATAGACTGGTAACCATTAGCTTTAGGCGCGGC
AATATAATCTTTGAAGCGGCCTGGCATTGGACGCCACAACTCGTGAATGTAACCGACCAT
AGCATAAACATCGCTCTGCGTTTCCATGACACAACGGATAGCAATCAAATCAAAAATCTG
ATCAAAGCGTTTTTTCTTGTCCCGCATTTTCCGATAAATGGAATAAATGTGTTTTGGTCG
ACCATAAACATCACCAAACAAGCCTTGCTCAGTGGTATAAGACTTGATTTTGGTAACAAT
ATCATCCACCAAAGCTTCACGCTCGCGACGTTTTTCATTCATCATATGGGAAATCTTATA
AAACTCCGTTTCGTTCAGGTAACGGAAAGCCAGATCTTCTAATTCCCATTTGATACGACT
AATCCCCAAGCGGTGCGCCAAGGGAGCATAAATTTCCATGGTTTCGCGCGAAATACGCTC
TTGCTTATCCTTACGCAGATGCTTGAGGGTCCGCATATTATGTAAACGGTCCGCCAATTT
CACCAAAATCACTCGAATGTCTTTGGACATGGCCATCAACATTTTACGGTGATTTTCAGC
TAACTGTTCTTCGTGCGATTTGTACTCTACCTTACCTAACTTGGTTACCCCATCAACAAT
ATCACGGACATCTTTGCCAAAATCAAATTCAATGTTATCTAGAGTAATATCAGTATCTTC
TACCACGTCATGCAAAAAACCACAGGCAACCGTCACAGCATCCAAATGCAAATCTGCCAG
AATCCCCGCCACTTGAATCGGATGCACAATGTAAGGCTCTCCTGACTTTCGCACTTGATA
AAAATGAGCAGCCGTTGCATAATCCAAAGCTTTTTTCACAAAGGCCGCATCGGTCTCATT
CATGTATTTGGCTGCTAAGGCAACAACTTCTTCTCCTGTTAAATTGATTTCTTTTGCCAT

# Drug_Target_2_General_Function:
Signal transduction mechanisms

# Drug_Target_2_General_References:
8232196	Mechold U, Steiner K, Vettermann S, Malke H: Genetic organization of the streptokinase region of the Streptococcus equisimilis H46A chromosome. Mol Gen Genet. 1993 Oct;241(1-2):129-40.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3107

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
83914

# Drug_Target_2_Name:
Putative GTP pyrophosphokinase

# Drug_Target_2_Number_of_Residues:
739

# Drug_Target_2_PDB_ID:
1VJ7

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01842	ACT
PF01966	HD
PF02824	TGS
PF04607	RelA_SpoT

# Drug_Target_2_Protein_Sequence:
>Putative GTP pyrophosphokinase
MAKEINLTGEEVVALAAKYMNETDAAFVKKALDYATAAHFYQVRKSGEPYIVHPIQVAGI
LADLHLDAVTVACGFLHDVVEDTDITLDNIEFDFGKDVRDIVDGVTKLGKVEYKSHEEQL
AENHRKMLMAMSKDIRVILVKLADRLHNMRTLKHLRKDKQERISRETMEIYAPLAHRLGI
SRIKWELEDLAFRYLNETEFYKISHMMNEKRREREALVDDIVTKIKSYTTEQGLFGDVYG
RPKHIYSIYRKMRDKKKRFDQIFDLIAIRCVMETQSDVYAMVGYIHELWRPMPGRFKDYI
AAPKANGYQSIHTTVYGPKGPIEIQIRTKEMHQVAEYGVAAHWAYKKGVRGKVNQAEQKV
GMNWIKELVELQDASNGDAVDFVDSVKEDIFSERIYVFTPTGAVQELPKDSGPIDFAYAI
HTQVGEKAIGAKVNGRMVPLTAKLKTGDVVEIVTNPNSFGPSRDWIKLVKTNKARNKIRQ
FFKNQDKELSVNKGRDMLVSYFQEQGYVANKYLDKKRIEAILPKVSVKSEESLYAAVGFG
DISPVSVFNKLTEKERREEERAKAKAEAEELVNGGEIKHENKDVLKVRSENGVIIQGASG
LLMRIAKCCNPVPGDPIEGYITKGRGIAIHRADCNNIKSQDGYQERLIEVEWDLDNSSKD
YQAEIDIYGLNRRGLLNDVLQILSNSTKSISTVNAQPTKDMKFANIHVSFGIPNLTHLTT
VVEKIKAVPDVYSVKRTNG

# Drug_Target_2_Reaction:
ATP + GTP = AMP + guanosine 3'-diphosphate 5'-triphosphate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
In eubacteria ppGpp (guanosine 3'-diphosphate 5-' diphosphate) is a mediator of the stringent response that coordinates a variety of cellular activities in response to changes in nutritional abundance. This enzyme catalyzes the formation of pppGpp which is then hydrolyzed to form ppGpp

# Drug_Target_2_SwissProt_ID:
Q54089

# Drug_Target_2_SwissProt_Name:
RELA_STREQ

# Drug_Target_2_Synonyms:
(P)ppGpp synthetase
ATP:GTP 3'- pyrophosphotransferase
EC 2.7.6.5
Stringent response-like protein
ppGpp synthetase I

# Drug_Target_2_Theoretical_pI:
8.80

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB02836
